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SUMMARY
ANCA are found in various systemic vasculitis and are supposed to play a role in the pathogenesis of the disease, in co-
operation with other factors such as cytokines. A total of 36 ANCA-positive and 10 ANCA-negative serum samples were
analysed for the presence of TNF soluble receptors (TNF-sR), which are shed from the surface of activated cells and may
act as TNF inhibitors. Of the ANCA-positive samples, 67% had elevated TNF-sR75 and 72% had elevated TNF-sR55
compared to ANCA-negative specimens (mean [S.E.] 18.7 [17.3] vs 3.6 [1.5] and 10.5 [9.7] vs 1.9 [0.7] ng/ml, P<0.01).
Elevation of TNF-sR in patients with ANCA suggests that cytokines and their inhibitors are involved in the pathogenesis
of ANCA-associated autoimmune diseases.
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ANTINEUTROPHIL cytoplasmic antibodies, specific for
constituents of neutrophil granules and monocyte lyso-
somes, are present in patients with various systemic
vasculitis. Two main types of staining patterns were dis-
tinguished on ethanol-fixed neutrophils used as sub-
strate for indirect immunofluorescence microscopy:
the cytoplasmic (cANCA) and the perinuclear
(pANCA) pattern. Most cANCA are raised against a
serine protease, termed proteinase 3 (PR3) or myelo-
blastine, and are associated with Wegener's granulo-
matosis, whereas pANCA have specificity for
myeloperoxidase or elastase and tend to be associated
with idiopathic crescentic glomerulonephritis or necro-
tizing vasculitis other than Wegener's [1, 2]. ANCA
levels correlate closely with disease activity, and
relapses of Wegener's granulomatosis are preceded by
a rise of cANCA levels [3, 4]. It thus follows that
ANCA may play a role in the pathogenesis of systemic
vasculitis. Indeed, it has been shown in vitro that both
cANCA and pANCA are able to activate neutrophil
respiratory burst and degranulation and to enhance
their chemotactic response to fMLP [5,6]. The result-
ing release of neutrophil proteases and reactive oxygen
species may damage endothelial cells, leading to vas-
cular necrosis. This neutrophil activation was most
effective after priming neutrophils with TNF-a, known
to enhance the expression of adhesion molecules on
neutrophils and vascular endothelial cells [5]. TNF
binds to two distinct receptors of 55 kDa (TNF-R55)
and 75 kDa (TNF-R75) [7], which are expressed in
nearly identical amounts at the neutrophil surface [8].
Upon exposure to chemotactic factors, neutrophils
shed their surface TNF-R and then release TNF
soluble receptors (TNF-sR) which may act as TNF
inhibitors [8,9]. We therefore tested sera for a possible
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relationship between the presence of ANCA and the
concentrations of TNF-sR and TNF-a.
MATERIALS AND METHODS
Serum specimens
A total of 46 serum samples sent to the laboratory for
ANCA analysis (19 cANCA-positive, 17 pANCA-
positive and 10 ANCA-negative) and 21 serum
samples obtained from normal blood donors were
analysed.
ANCA determination
ANCA concentrations were determined by flow
cytometry using fixed neutrophils as targets [10].
ANCA-positive specimens were further characterized
by indirect immunofluorescence to distinguish
pANCA staining from cANCA staining [5,11].
TNF-sR measurement
TNF-sR55 and TNF-sR75 were assayed by enzyme-
linked immunological biological assay (ELIBA; F
Hoffmann-La Roche, Basel, Switzerland) as pre-
viously described [12]. Briefly, 96-well microtitre plates
were coated with either monoclonal antibodies to
TNF-sR55 (clone htr-20) or to TNF-sR75 (clone utr-4),
and saturated with bovine serum albumin (Sigma Ltd,
St Louis, MO). Microtitre plates were washed and
100 ^1 of standard (human recombinant TNF-sR55
and TNF-sR75), or diluted samples were dispensed
onto the plates. Horseradish peroxidase-conjugated
human recombinant TNF-a was added to the wells, and
plates were incubated overnight at room temperature
in a single-step reaction. After washing, tetramethyl-
benzidine H2O2 was added and incubated for 15 min.
The reaction was stopped with H2SO4 and absorption
read at 450 nm. The concentrations of TNF-sR55 and
TNF-sR75 in the samples were determined by interpol-
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ation from the standard curve. The addition of up to
10 ng/ml of recombinant human TNF-oc had no effect
on the TNF-sR assay, the sensitivity of which was
150 pg/ml.
TNF-a measurement
A commercially available ELISA was used to
measure TNF-a (TNF-a EASIA; Medgenix Ltd, Fleu-
rus, Belgium). Preliminary experiments showed that
TNF-a determinations were similar in the presence of
various concentrations of both types of human recom-
binant TNF-sR (up to 15 ng/ml for hrTNF-sR75 and up
to 10 ng/ml for hrTNF-sR55) as in buffer in this assay
(Table I). We assume therefore that the totality of
TNF-a present in serum, both free and bound to
TNF-sR, was measured and that the immunoassay was
not hampered by the presence of high levels of TNF-
sR55 or TNF-SR75.
IL-8 measurement
IL-8 was assayed by a commercially available
ELISA (Research and Diagnostic Systems, Minneapo-
lis, MN, USA) according to the supplier's instructions.
Statistics
Results are expressed as mean ± S.D. Data were sub-
jected to the Kruskal-Wallis analysis of variance and
Bonferroni equality test.
RESULTS
ANCA-positive sera — consisting of cANCA and
pANCA — contained significantly higher concentra-
tions of TNF-SR55 (10.5 ± 9.7 ng/ml) and TNF-sR75
(18.7 ± 17.3 ng/ml) than normal sera obtained from
healthy blood donors (1.6 ± 0.3 and 2.1 ± 0.5 ng/ml of
TNF-sR55 and TNF-sR75, respectively) (P<0.01).
The elevation of TNF-sR concentrations was also sig-
nificant as compared to ANCA-negative samples sub-
mitted for ANCA analysis (1.9 ± 0.7 and
3.6 ± 1.5 ng/ml of TNF-sR55 and TNF-sR75, respect-
ively) (P<0.01). When ANCA-positive sera were dis-
criminated according to their immunofiuorescence
pattern, pANCA-positive sera contained six- to seven-
fold higher concentrations of both TNF-sR55
(13.2 ± 9.7 ng/ml) (P<0.01) and TNF-sR75
(25.1 ± 16.8) (P<0.01) than did ANCA-negative
samples, while the increase in cANCA-positive sera
was less striking (8.0 ± 9.2 and 13.0 ± 16.0 ng/ml of
TNF-sR55 and TNF-sR75, respectively) but neverthe-
less statistically significant for TNF-sR55 (P <0.05)
(Fig. 1, upper and middle panels). In addition, a higher
percentage of patients positive for pANCA showed
elevated levels of TNF-sR55 and TNF-sR75 as com-
pared to patients positive for cANCA (82 vs 53%, and
82 vs 63%, respectively), elevated level being defined
as a value above mean + 2 S.D. of ANCA-negative
samples. However, there was no relationship between
ANCA concentrations as defined by fluorescence
intensity and TNF-sR concentrations in serum (data
not shown).
High TNF-a levels were also observed in both
ANCA-positive groups, however without any clear
correlation with TNF-sR levels. Elevated TNF-a in two
ANCA-negative patients as compared to normal sera
suggested an ANCA-unrelated inflammatory process
(Fig. 1, lower panel).
DISCUSSION
The finding of a close correlation between the pres
ence of ANCA and elevated levels of both types of
TNF-sR in vasculitis serum provides additional evi-
dence of the role of ANCA in the pathogenesis of vas-
culitis. It strongly suggests that ANCA-induced
neutrophil activation that was demonstrated in vitro [5,
6] also occurs in vivo. It is likely that ANCA-induced
neutrophil degranulation and release of proteolytic
enzymes, such as elastase — known to cleave TNF
receptors [8] — lead to the shedding of TNF-sR from
the neutrophil surface. It is also possible that the intra-
cellular pool of TNF-R55 located in neutrophil-specific
granules is a source of TNF-sR55 released after
degranulation [13]. However, both types of TNF-sR
are increased in ANCA-positive sera and there was a
positive correlation between them, suggesting that the
latter mechanism was not the main source of TNF-sR
in these sera.
TNF-sR levels determined in ANCA-positive sera
were remarkably elevated as compared to those
measured in chronic rheumatic diseases such as RA
(range of TNF-sR55 : 1.0-2.7 ng/ml and range of TNF-
TABLEI
Effect of the addition of TNF-sR on TNF-a levels
(pg/ml)
0
7.5
25
75
250
750
Buffer
0
3
15
54
183
606
TNF-a levels (pg/ml) in the
sR55 sR75
0.65
0
3
17
53
186
597
0
3
15
43
118
443
sR55
1.
0
3
14
45
182
595
sR75
25
0
4
16
54
173
569
presence of hrTNF-sR55 and -sR75
sR55 sR75
25
14
4
17
50
169
547
0
3
24
50
179
582
sR55
0
6
18
54
191
566
sR75
5
0
4
17
52
214
558
(ng/ml)
sR55 sR75
10
0
6
22
58
209
606
0
5
16
55
193
538
sR55
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
sR75
15
0
5
17
49
217
663
TNF-a levels were measured in the presence of hrTNF-sR buffer and of increasing concentrations of both types of hrTNF-sR, using
the Medgenix TNF-a EASIA.
n.d., Not done.
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FIG. 1.—Levels of TNF-sR55 (upper panel), TNF-sR75 (middle
panel) and TNF-a (lower panel) in cANCA-positive (« = 19),
pANCA-positive (n = 17), ANCA-negative (n = 10) and
normal (n = 21) serum samples.
sR75 : 2.5-6.8 ng/ml) [12, 14] or polymyositis (1.1-
7.5 ng/ml and 3.0-16.1 ng/ml) (manuscript in prep-
aration). However, levels of TNF-sR reached in
ANCA-positive sera remained below the ones we
observed in meningococcaemia (5-136 ng/ml and 10-
145 ng/ml) [15,16]. Further studies will be necessary to
accurately compare TNF-sR levels in various chronic
diseases and to assess whether there is a relationship
with the pathogenesis or with the course of the disease.
TNF-sR released after neutrophil degranulation
may compete for TNF-a with TNF cell surface recep-
tors on other neutrophils as well as on surrounding
endothelial cells [2,17] and thus act as a TNF-a antag-
onist [18], protecting the cells against further activation
and toxicity of high levels of TNF-a. On the other
hand, TNF-sR have been shown in vitro to preserve
TNF-a activity by stabilizing its trimeric structure [19]
and may thus contribute to the amplification of
ANCA-mediated neutrophil activation. These dual
activities of TNF-sR might explain why we did not find
a clear correlation between TNF-sR levels and ANCA
concentrations.
A recent study revealed elevated TNF-a levels in the
serum of Wegener's patients during the active phase
and their absence during remission [17]. Those results
are not inconsistent with our findings, since ANCA-
positive sera were obtained from patients at different
stages of the disease and we did not investigate the
relationship between TNF-sR levels and disease activ-
ity. The presence of TNF-sR55 or -sR75 did not impair
TNF-a determination by the ELISA we used; there-
fore, low levels of TNF-a detected in serum could not
be imputed to interferences with soluble receptors. It is
more likely that a transient increase in TNF-a, which is
able to prime neutrophils and to enhance ANCA-
induced neutrophil activation [5,6], may have escaped
detection due to the short half-life of TNF-a, but
nevertheless triggered an elevation of TNF-sR concen-
trations remaining in the serum for prolonged periods.
Two recent studies demonstrate that serum levels of
another soluble receptor — IL-2 soluble receptor
(IL-2sR) — correlate with disease activity in patients
with Wegener's granulomatosis [20,21]. However, the
presence of IL-2sR has a completely different signifi-
cance since it is mainly a marker of T cell activation and
does not have a proven inhibitory effect on IL-2 activ-
ity [22].
Upon exposure to TNF-a or interleukin-1, endo-
thelial cells, fibroblasts and other cell types produce
IL-8 which is one of the main chemoattractants for neu-
trophils [23]. In addition, IL-8 along with TNF-a pro-
motes the translocation of PR3 from their
intragranular loci to the neutrophil surface and then
renders the autoantigen accessible to ANCA [2]. IL-8
is therefore likely to be involved in ANCA-mediated
pathogenesis of vasculitis. However, in preliminary
experiments, elevated levels of IL-8 were detectable in
few ANCA-positive sera (five of 15 pANCA and six of
17 cANCA). None of the ANCA-negative sera con-
tained IL-8 concentrations above the limit of detection
(93 pg/ml). No correlation was found between IL-8
TNF-a levels or between IL-8 and TNF-sR levels (data
not shown). This may be due to the fact that IL-8 acts
mainly at the local level and does not circulate at con-
centrations detectable by the immunoassay we have
used. It is also possible that IL-8 was elevated only
during the initial phase of the vasculitis and no longer
detectable in our specimens obtained at different
stages of the disease.
Although there is still no direct evidence to demon-
strate the pathogenic effect of ANCA in vivo, the pres-
ence of elevated levels of TNF-sR in ANCA-positive
serum is an important element in the understanding of
the pathogenesis of some systemic vasculitides. The
balance between TNF-a and TNF-sR is probably a
critical factor in the pathophysiological process, but
further investigations and prospective studies will be
necessary to fully understand its role and its relation-
ship with disease activity.
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